Proportion of reimbursement of targeted drugs for lung cancer in Sichuan

70%—90%。 In 2022, the proportion of reimbursement for targeted drugs for lung cancer will be 70%-90% for outpatients and 85%-99. 1% for inpatients. Lung cancer targeted drugs and immune drugs included in the scope of medical insurance reimbursement are: gefitinib, erlotinib, ectinib, afatinib, dakotinib, oxitinib, amitinib, fumitinib and erlotinib.